Since 2011, when the Xarelto (Rivaroxaban) was approved by the U.S. Food and Drug Administration to treat atrial fibrillation, there have been over 2,100 reports made to the FDA regarding adverse side effects involving the drug, with over 1,800 listing Xarelto as the primary culprit. Atrial fibrillation is a condition that causes blood to pool in the storage chamber of the heart where it can clot and travel to the brain. Via legalexaminer. Posted July 8, 2014. –Alanna McCatty
